A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers

Inclusion Criteria: * Patients must have histologically or cytologically confirmed advanced cancer that is: * HER2 amplified (IHC 2+ or greater) based on archived tumor evaluation * Heregulin positive based on a study required fresh biopsy sample performed at screening and confirmed by central laboratory * Patients must have blocks of archived formalin-fixed, paraffin-embedded tumor tissue available for sectioning and immunohistochemical staining * Patient's cancer must have recurred or progressed following standard therapy, have not responded to standard therapy, or for which no standard therapy exists. * Patients must be \>= 18 years of age * Patients or their legal representatives must be able to understand and sign an informed consent * Patients may have measurable or non-measurable tumor(s) * Patients should have ECOG Performance Score (PS) 0 or 1 * Patients must have adequate bone marrow reserves as evidenced by: * Absolute neutrophil count (ANC) \>= 1,500/uL and * Platelet count \>= 100,000/uL * Hemoglobin \>= 9 g/dL * Patients must have tumor tissue amenable to biopsy * Patients must be willing to undergo biopsy prior to treatment to MM-111 Exclusion Criteria: * Patients for whom potentially curative antineoplastic therapy is available * Patients who are pregnant or lactating * Patients with an active infection or with an unexplained fever greater than 38.5 C during screening visits or on the first scheduled day of dosing. (At the discretion of the investigator, patients with tumor fever may be enrolled) * Patients with untreated and/or symptomatic primary or metastatic CNS malignancies (patients with CNS metastases who have undergone surgery or radiotherapy, whose disease is stable, and who have been on a stable dose of corticosteroids for at least 2 weeks prior to the first scheduled day of dosing will be eligible for the trial * Patients with known hypersensitivity to any of the components of MM-111 or who have had hypersensitivity reactions to fully human monoclonal antibodies (patients with a history of hypersensitivity to trastuzumab, a humanized antibody, are not excluded) * Patients with known HIV, hepatitis B or C (if patients have previously been treated for C and have undetectable viral loads, they can be considered eligible for the trial)